| Literature DB >> 35858928 |
Zheng-Rong Gao1, Yun-Zhi Feng1, Ya-Qiong Zhao1, Jie Zhao1, Ying-Hui Zhou2, Qin Ye1, Yun Chen1, Li Tan1, Shao-Hui Zhang1, Yao Feng1, Jing Hu1, Ze-Yue Ou-Yang1, Marie Aimee Dusenge1, Yue Guo3.
Abstract
Bone tissue engineering (BTE) is a promising method for the repair of difficult-to-heal bone tissue damage by providing three-dimensional structures for cell attachment, proliferation, and differentiation. Traditional Chinese medicine (TCM) has been introduced as an effective global medical program by the World Health Organization, comprising intricate components, and promoting bone regeneration by regulating multiple mechanisms and targets. This study outlines the potential therapeutic capabilities of TCM combined with BTE in bone regeneration. The effective active components promoting bone regeneration can be generally divided into flavonoids, alkaloids, glycosides, terpenoids, and polyphenols, among others. The chemical structures of the monomers, their sources, efficacy, and mechanisms are described. We summarize the use of compounds and medicinal parts of TCM to stimulate bone regeneration. Finally, the limitations and prospects of applying TCM in BTE are introduced, providing a direction for further development of novel and potential TCM.Entities:
Keywords: Bone regeneration; Bone tissue engineering; Osteogenesis; Scaffolds; Traditional Chinese medicine
Year: 2022 PMID: 35858928 PMCID: PMC9297608 DOI: 10.1186/s13020-022-00640-5
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 4.546
The classification standard of TCM
| Classification standard | Category | References |
|---|---|---|
|
| Top-grade | [ |
| Medium-grade | ||
| Low-grade | ||
|
| Sources, habitats, colors, parts of plants, and how they were collected, processed, and selected for prescriptions | [ |
| Four fundamental characters: cold, cool, warm, and hot | [ | |
| Five fundamental tastes: salty, sour, bitter, sweet, and pungent | ||
| Four toxic states: toxic, nontoxic, very toxic, and slightly toxic | ||
| 12 meridians: bladder, spleen, large intestine, stomach, small intestine, liver, cardiovascular, heart, kidney, gallbladder, pericardium and san jiao | ||
|
| Herb-derived medicine, animal-derived medicine and mineral-derived medicine | [ |
|
| ||
| Chinese Pharmacopoeia | ||
| Active components | Alkaloids | [ |
| Terpenoids | ||
| Flavonoids | ||
| Volatile Oils | ||
| Lignanoids | ||
| Coumarins | ||
| Quinones | ||
| Phenols | ||
| Glycosides | ||
| Saponins | ||
| Stilbenes | ||
| Phenols | ||
| Esters |
The basic information of TCM
| Category | Components | Structural forms | Molecular weight | Source | Main function | References |
|---|---|---|---|---|---|---|
| Flavonoids | Icariin |
| 676.67 |
| Treatment of fractures, joint disease, and gonadal dysfunctions | [ |
| Icaritin |
| 386.4 |
| Osteoprotective effect, neuroprotective effect, cardiovascular protective effect, anti-cancer effect, anti-inflammation effect, and immune-protective effect | [ | |
| Hydroxy safflower yellow A |
| 612.53 |
| Cardiovascular protection, coronary heart disease treatment and capillary angiogenesis, blood circulation and dispersing blood stasis | [ | |
| Xanthohumol |
| 354.4 |
| Stimulate osteogenic differentiation, anti-inflammatory, and inhibits osteoclastogenesis | [ | |
| Kaempferol |
| 286.23 |
| Osteoporosis, diabetes, obesity, immune regulation, antiviral, and antidepressant treatments | [ | |
|
| Not applicable (NA) | N/A |
| Osteoporosis treatment | [ | |
| Baicalin |
| 446.36 |
| Antioxidant, antiapoptotic, and immunoregulatory activities with minimal side-effects | [ | |
| Baicalein |
| 270.24 |
| Antioxidant, antiapoptotic, and immunoregulatory activities with minimal side-effects | [ | |
| Naringin |
| 580.53 | Tomatoes, grapefruits, and many other citrus fruits | Anti-inflammatory, antiapoptotic activities, and have therapeutic potential cancer, cardiovascular disease, diabetes, and oral disease | [ | |
| Hesperetin |
| 302.28 | Chenpi | Antioxidant, anti-inflammatory, and anti‐carcinogenic effects | [ | |
| Quercetin |
| 302.24 |
| Anti-inflammatory, anti-viral, anti-oxidant, anti-cancer properties, osteogenesis and angiogenesis | [ | |
| Silymarin |
| 482.44 |
| Hepatoprotective effects, anti-viral, anti-Parkinson, anti‐Alzheimer effects, anti-cancer and anti‐inflammatory | [ | |
| Alkaloids | Tetrandrine |
| 622.76 |
| Anti-inflammatory, immunosuppressant, anti-allergic effects, anti-oxidant, anti-diabetic and anti-microbial | [ |
| Berberine |
| 336.36 |
| Diabetes, anti-inflammation, anti-cancer therapies, lowing of blood lipids and promote bone formation | [ | |
| Glycosides | Ginsenoside Rg1 |
| 801.01 | Ginseng | Cell proliferation and differentiation, anti-apoptosis, and anti-inflammation | [ |
| Ginsenoside Rb1 |
| 1109.31 | Ginseng | Osteogenesis | [ | |
| Terpenoids | Ursolic acid |
| 456.70 | Fruits and vegetables | Anticancer, antioxidant, and other pharmacological effects | [ |
| Polyphenols | Resveratrol |
| 228.25 |
| Mediating inflammation, tumerogenesis, and cardioprotective effects | [ |
| Curcumin |
| 368.39 |
| Anti-oxidant, anti-inflammatory, and anti-cancer effects | [ | |
| Epigallocatechin gallate |
| 458.38 |
| Anti-oxidant and anti-inflammatory effects | [ |
Fig. 1Schematic diagram representing the application of traditional Chinese medicine in bone tissue engineering to accelerate bone regeneration
Fig. 2The osteogenic mechanism of TCM ingredients
Promoting proliferation, osteogenesis and mineralization
| Active components | Biomaterials | Experimental models | Efficacy | References |
|---|---|---|---|---|
| Icariin | SF/SBA15 | Rat BMSC (rBMSC), 38.4 µM | Up-regulating RUNX2, ALP, OCN, and COLI | [ |
| SF/PLCL nanofibrous membrane | rBMSC, 10−5 mol/L; rat calvarial defects model | Up-regulating ALP activity | [ | |
| PLGA microspheres | rBMSC, 4 × 10−3 M; rat calvarial defects model | Up-regulating RUNX2, ALP, OCN, COLI, and OPN | [ | |
| Col/PCL/HAp composite scaffolds | rBMSC; rabbit tibial plateau defects model | Up-regulating ALP, COLI, OCN, and OPN | [ | |
CS-modified halloysite nanotubes | hASCs, 10−5 M; | Up-regulating ALP | [ | |
| CS/nHAP | Osteoblast | N/A | [ | |
| PCL/Gel | MC3T3-E1, 0.05 wt% | Up-regulating ALP, OCN, COLI, and calcium content | [ | |
| PLGA/TCP | MC3T3-E1, 0.32%; SAON rabbit distal femur defect model; | Up-regulating BSP, OCN, and ALP | [ | |
| TCP | Ros17/28, 5 × 10−5 M | Up-regulating ALP | [ | |
| PHBV scaffolds | MC3T3-E1, MG-63, 25 mg/mL | Up-regulating BGN, BMP-2, BMP-6, and BMP-7 | [ | |
| BioCaP | MC3T3-E1, 5 mg/L; rat calvarial defects model | Up-regulating ALP, OCN, RUNX2, BMP-2, and COLI | [ | |
| ECM-SIS | MC3T3-E1, 10−5 M; mouse calvarial defect model | Up-regulating ALP, BSP, OCN, and BMP-4 | [ | |
| Icaritin | PLGA/TCP | Rabbit BMSC, 0.74 g/kg; rabbit bilateral thigh muscles model | Up-regulating ALP and calcium deposition | [ |
| PLGA/TCP | Rabbit BMSC, 1.4 × 10−3 M; | Up-regulating COLI, ALP, OCN and calcium deposition | [ | |
| Hydroxy safflower yellow A | BG | rBMSCs, HUVECs; rat calvarial defects model | Up-regulating RUNX2, OPN, OCN, ALP and BMP-2 | [ |
| Xanthohumol | HA-g-PLLA | MC3T3-E1, 5, 10, 20 wt% | N/A | [ |
| Kaempferol | TiO2 | rBMSC; rat femur defect | Up-regulating RUNX2, OCN, ALP, OPN and ON | [ |
| Zn | MG-63, 25 µM; Zebrafish model | Up-regulating RUNX2, COLI, ALP, OCN, and ON | [ | |
| Baicalin and baicalein | Ca-polyP | Primary human osteoblasts, 3 µg/mL | Up-regulating calcium, calcium efflux channel, PMCA and ALP | [ |
| Naringin | SF/HAp | hUCMSCs, 0.1 wt%; rabbit femoral distal bone defect | Up-regulating ALP, RUNX2, OSX and COL1A and promoting AKT and PI3K phosphorylation | [ |
| microsphere/SAIB hybrid depots | Primary osteoblasts, 4% w/w; mouse calvarial defect model | Up-regulating ALP, RUNX2 and OCN | [ | |
| CS | UMR106, 5 wt%; | Up-regulating ALP | [ | |
| PLGA/PLLA/PDLLA | MC3T3-E1, 7 wt%; | N/A | [ | |
| PLGA | Rat calvarial defects model | Up-regulating BMP-2, OSX, OPN, BSP, COLI, OCN and calcium content | [ | |
| Hesperetin | Gel | hMSC, 1 µM; rat tibial osteotomy model | Up-regulating RUNX2, ALP, OCN and COLI and promoting ERK and Smads-1/5/8 phosphorylation | [ |
| Quercetin | Ti | hMSCs, 64 ± 10 and 842 ± 361 nmol | Up-regulating ALP activity and calcium content | [ |
| DC/HAp | Rabbit BMSCs, 25 µM; rat calvarial defect model | Up-regulating RUNX2, OCN, and COLI | [ | |
| PLLA | MC3T3-E1, 200 µM | Up-regulating RUNX2, ALP, OCN, and COLI | [ | |
| MSCS/PCL | Wharton’s jelly MSC, 2% | Up-regulating calcium deposit | [ | |
| Decellularized goat-lung scaffold | BMSC, 100 µM | Up-regulating ALP and calcium deposits | [ | |
| Ti | hUCMSCs, HGF, 50 nM | Up-regulating RUNX2, COL, OCN, and ALP | [ | |
| Silymarin | DC/HAp | rBMSCs, 100 µM; rat calvarial bone defect model | Up-regulating RUNX2, COLI, and OCN | [ |
| PLA/Carbon nanotubes | Wharton’s jelly MSCs; rat calvarial bone defect model | Up-regulating ALP | [ | |
| Silibinin | Zn | C3H10T1/2, MG-63, 60 µM | Up-regulating RUNX2, COLI, ALP, OCN, and miR-590/Smad-7 pathway | [ |
| Alginate/Gel | C3H10T1/2, 20, 50, 100 µM | Up-regulating RUNX2, COLI, OCN, ALP, Pre-miR-20b and pre-miR-410 and down-regulating pre-miR-30c-1and pre-miR-221 | [ | |
| Berberine | PCL/COL | DPSCs, 50 µg/mL; rat calvaria defects model | Up-regulating ALP, BMP-2, COLI and RUNX2 | [ |
| PCL/PVP-MC/CS bilayer membrane | MC3T3-E1, 10 µM; rat femur defect model | N/A | [ | |
| Negatively charged | MG-63, rBMSCs; rabbit lateral femoral condyle model | Up-regulating ALP and OCN | [ | |
| Ginsenoside Rg1 | SF/PCL | MC3T3-E1, HUVECs, 5% w/w | Up-regulating ALP, BMP-2, RUNX2 and OCN | [ |
| Ginsenoside Rb1 | MSCS/PCL | hDPSCs, 5% v/v; rabbit femoral defect model | Up-regulating ALP, OPN and OCN | [ |
| Ursolic acid | MBG/CS porous scaffolds | hBMSCs, MC3T3-E1, 5 µM; rat calvarial defect model | Up-regulating ALP, COLI, RUNX2 and BMP-2 and promoting Smad1/5 phosphorylation | [ |
| Resveratrol | PEGDA/TCS hydrogel | rBMSCs, HUVECs, 800 µM; rat tibia defect model | Up-regulating Ki67, RUNX2, OPN, and calcium content | [ |
| PLGA microsphere | hMSCs, hTHP-1 monocytes, 25 µM | Up-regulating ALP, OCN and calcium content | [ | |
| SLNs/GelMA | rBMSCs, 0.02% w/v; rat calvarial critical-size defect model | Up-regulating ALP, OCN, RUNX2 and OPN | [ | |
| PLA/OMMT | hASCs, 0.1 wt% | Up-regulating ALP, OCN and OPN | [ | |
| Curcumin | PCL | MC3T3-E1, 1 wt% | Up-regulating RUNX2, ALP, BMP-2, OCN, and OPN | [ |
| Epigallocatechin gallate | Ti-6Al-4 V | hADSCs, Raw264.7, 0.1, 0.5, 1 mg/mL; rabbit tibias defect model | Up-regulating calcium content, RUNX2, OSX, OCN, OPN | [ |
| PLLA | ADSCs, Raw 264.7, 1 mg/mL; mouse calvarial defect | Up-regulating ALP, RUNX2, and OPN | [ | |
| Gel sponges | UMR106, 0.07 mg; rat calvarial defects model | Down-regulating MMP-2, and MMP-9 | [ | |
| POSS | MC3T3-E1, 6 wt% | Up-regulating ALP | [ | |
| DC/HAp | Rabbit BMSC, 5 µM; nude mouse model | Up-regulating RUNX2, OCN, and COLI | [ | |
| Gel sponges | Rat calvarial defects model | N/A | [ | |
| Genipin | CS framework | 5 mg | Up-regulating RUNX2, OCN, OPN, and ALP | [ |
| CS | 5 mg | Up-regulating RUNX2, OCN, OPN, and ALP | [ | |
| Silica particles | 20 mM | Up-regulating ALP | [ | |
| Proanthocyanidins | COLI | 10% | Up-regulating ALP | [ |
Chondrogenesis
| Active components | Biomaterials | Experimental model | Efficacy | References |
|---|---|---|---|---|
| Icariin | HA/Col hydrogel | BMSC, 1 µM; rabbit osteochondral defect model | Up-regulating SOX9, AGG, COL II, and COL X | [ |
| COL | Rabbit chondrocyte, 10−5 M; rabbit distal femora osteochondral defects model | Up-regulating AGG, COLII, SOX9, GAG, and COLI | [ | |
| Selfassembling peptide nanofiber hydrogel | rBMSC; 1 × 10−6 M | Up-regulating COLII and SOX9 | [ | |
| Resveratrol | COLI/PAA | Chondrocytes, BMSCs, 0.5%; rabbit osteochondral defects model | Up-regulating SOX9, AGG, COLII and COLI | [ |
| PLA–Gel porous nano-scaffold | Rat articular cartilage defect model | Up-regulating AKT and COLII and down-regulating PI3K/AKT signaling pathway-related proteins (VEGF, PTEN, Caspase9 and MMP-13) | [ | |
| Epigallocatechin | Hyaluronic acid | Chondrocytes, 50 µM; mouse osteoarthritis model | Up-regulating GAG, COLII, SOX9 and ACAN and down-regulating ADAMTS5, COLI, and COLX | [ |
| Genipin | Carbon dot hydrogel | 500 mM | Collagen–genipin–carbon dot nanoparticles improving chondrogenic differentiation and cartilage regeneration | [ |
Angiogenesis
| Active components | Biomaterials | Experimental model | Efficacy | References |
|---|---|---|---|---|
| Icariin | CPC | rBMSC, 20 µM; OVX rat calvarial defect model | Up-regulating VEGF and ANG1 | [ |
| SMC-PHBHHx scaffold | BMSC, 10−6 mol/L; rat calvarial defects model | Up-regulating VEGF, and FGF | [ | |
| 45S5 Bioglass | rADSC, 10−7 mol/L; rat calvarial defects model | Up-regulating VEGF | [ | |
| Icaritin | PLGA/TCP | BMSC, BMC 0.052: 100 (powder weight to solution volume); rat calvarial defect model | Up-regulating OCN | [ |
| PLGA/TCP | Rabbit ulnar segmental bone defect | N/A | [ | |
| PLGA/TCP | rBMSC, 1 µM; SAON rabbit both distal and proximal femur defect model | MEK/ERK and PI3K/Akt/eNOS-dependent signal pathways | [ | |
| Hydroxy safflower yellow A | BG | rBMSCs, HUVECs; rat calvarial defects model | Up-regulating HIF-1α | [ |
| Silibinin | Zn | C3H10T1/2, MG-63; 60 µM; 3, 7 d | Up-regulating VEGF and ANG1 | [ |
| Resveratrol | PEGDA/TCS Hydrogel | rBMSCs, HUVECs, 800 µM; rat tibia defect model | Up-regulating CD31 | [ |
| PLGA microsphere | hMSCs, hTHP-1 monocytes, 25 µM | Up-regulating VEGF | [ |
Osteoclastogenesis
| Active components | Biomaterials | Experimental model | Efficacy | References |
|---|---|---|---|---|
| Icariin | CPC | rBMSC, 20 µM; OVX rat calvarial defect model | Down-regulating RANKL | [ |
| Icaritin | PLGA/TCP | BMSC, BMC 0.052: 100 (powder weight to solution volume); rat calvarial defect model | Down-regulating RANKL/OPG | [ |
| Quercetin | Ti | RAW264.7, 1 mM; rabbit tibia model | Down-regulating Trap, CalcR, Ctsk, H+ATPase, MMP-9 and RANKL | [ |
| Ursolic acid | Ti particle | RAW264.7, BMMs, 5 µM; mouse calvarial bone defect model | Down-regulating NFATc1, NF-kB and JNK signaling | [ |
| Epigallocatechin | Ti-6Al-4 V | hADSCs, Raw264.7, 0.1, 0.5, 1 mg/mL; rabbit tibias defect model | Down-regulating TRAP, CTSK, and RAW264.7 number | [ |
| PLLA | ADSCs, Raw 264.7, 1 mg/mL; mouse calvarial defect | Down-regulating RAW264.7 number | [ |
Adipogenesis
| Active components | Biomaterials | Experimental model | Efficacy | References |
|---|---|---|---|---|
| Icaritin | PLGA/TCP | Rabbit BMSC, 3T3-L1, 10−6 M; SAON emu proximal femur defect model; SAON rabbit distal femur defect model | Down-regulating C/EBP, aP2, PPAR-γ and lipid droplet | [ |
| PLGA/TCP | BMSC, BMC 0.052: 100 (powder weight to solution volume); rat calvarial defect model | Down-regulating PPAR-γ2 | [ | |
| Gel hydrogels | hMSC, 100, 200 nM; SAON rat femoral head defect | Down-regulating PPAR-γ and c-Src | [ | |
| Curcumin | Silk hydrogel | hBMSC; 12.5 µM | Down-regulating PPAR-γ, LPL, FABp4 and Glut4 | [ |
| Epigallocatechin gallate | PLLA | ADSCs, Raw 264.7, 1 mg/mL; mouse calvarial defect | Down-regulating LPL and PPAR-γ | [ |
Others
| Mechanism | Active components | Biomaterials | Experimental models | Efficacy | References |
|---|---|---|---|---|---|
| Anti-bacterial properties | Silibinin | Zn | C3H10T1/2, MG-63, 60 µM |
| [ |
| Anti-bacterial properties | Berberine | Negatively charged | MG-63, rBMSCs; rabbit lateral femoral condyle model |
| [ |
| Anti-bacterial properties | Quercetin | Ti-6Al-4 V | MC3T3-E1 |
| [ |
| Anti-apoptotic properties | Ginsenoside Rg1 | Alginate-CS microspheres | hBMSC, 2 g | Up-regulating Nestin, NSE, GFAP and Bcl-2 and down-regulating Bax | [ |
| Anti-inflammatory properties | Resveratrol | PLA–Gel porous nano-scaffold | Rat articular cartilage defect model | Up-regulating SIRT1 | [ |
| Anti-inflammatory and anti-apoptotic properties | Baicalin | TPGS polymeric micelles | Rat gingival fibroblasts, 20 mg/mL; rat periodontal disease model | Down-regulating TNF-α, IL-1β, and the number of inflammatory cells | [ |
| Anti-inflammatory properties | Tetrandrine | PLLA | RAW 264.7, 20 mg; rat model | Down-regulating NO, TNF-a, IL-6, iNOS, and COX-2 | [ |
| Anti-inflammatory properties | Ginsenoside Rb1 | MSCS/PCL | hDPSCs, 5% v/v; rabbit femoral defect model | Up-regulating IL-1RA and down-regulating IL-1β | [ |
| Anti-inflammatory properties | Resveratrol | COLI/PAA | Chondrocytes, BMSCs, 0.5%; rabbit osteochondral defects model | Down-regulating IL-1β, MMP-13 and COX-2 | [ |
| Anti-inflammatory properties | Resveratrol | PLGA microsphere | hMSCs, hTHP-1 monocytes, 25 µM | Up-regulating IL-10 and down-regulating TNF-α and IL-6 | [ |
| Anti-inflammatory properties | Epigallocatechin gallate | Ti-6Al-4 V | hADSCs, Raw264.7, 0.1, 0.5, 1 mg/mL; rabbit tibias defect model | Up-regulating IL-10 and down-regulating IL-6 | [ |
| Anti-inflammatory properties | Epigallocatechin gallate | Hyaluronic acid | Chondrocytes, 50 µM; mouse osteoarthritis model | Down-regulating IL-1β and TNF-α, | [ |
| Anti-oxidant and anti-inflammatory properties | Epigallocatechin gallate | POSS | MC3T3-E1, 6 wt% | Down-regulating IL-6 | [ |
| Anti-oxidant and anti-inflammatory properties | Epigallocatechin gallate | Gel sponges | UMR106, 0.07 mg; rat calvarial defects model | Down-regulating 4-HNE | [ |
| Anti-oxidant properties | Resveratrol | PLA/OMMT | HASCs, 0.1 wt% | N/A | [ |
| Anti-oxidant properties | Quercetin | CS/COL hydrogel | hPDLSC; 100 µM | N/A | [ |
| Anti-oxidant properties | Epigallocatechin gallate | PLLA | ADSCs, Raw 264.7, 1 mg/mL; mouse calvarial defect | N/A | [ |